Eyenovia, Inc. is a clinical stage biopharmaceutical company. The Company is engaged in developing a pipeline of micro-doses therapeutics products utilizing the patented piezo-print delivery technology. Eyenoviaâ€™s pipeline is focused on the late-stage development of microdosed medications for mydriasis, myopia progression, glaucoma, and other eye diseases. MicroStat is a combination micro-formulation product (phenylephrine-tropicamide) candidate for pharmacologic mydriasis (eye dilation). MicroPine is topical treatment for progressive myopia, a back-of-the-eye disease. MicroProst is latanoprost formulation product candidate, which is being developed for the reduction of IOP in patients with Chronic Angle Closure Glaucoma (CACG), as well as Primary Open Angle Glaucoma (POAG) and Ocular Hypertension. MicroTears is a micro-droplet ocular hyperemia (red eye), pruritis (itch) and ocular lubrication product.